The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.

abstract：:Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...

journal_title：Thoracic cancer

authors： Okamura K,Fukuda Y,Soda H,Ogawara D,Iwasaki K,Fuchi S,Suyama T,Yoshida M,Harada T,Fukuda M,Mukae H

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictiv...

journal_title：Thoracic cancer

authors： Ishii H,Azuma K,Kawahara A,Kinoshita T,Matsuo N,Naito Y,Tokito T,Yamada K,Akiba J,Hoshino T

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:To distinguish early-stage lung cancer from benign disease in pulmonary nodules, especially lesions with ground-glass opacity (GGO), we assessed gene mutations of ctDNA in peripheral blood using targeted next-generation sequencing (NGS). METHODS:Single pulmonary nodule patients without mediastinal lymph nod...

journal_title：Thoracic cancer

authors： Jiang N,Zhou J,Zhang W,Li P,Liu Y,Shi H,Zhang C,Wang Y,Zhou C,Peng C,Zhang W,Hao Y,Sun Q,Li Y,Zhao X

更新日期：2020-11-16 00:00:00

abstract：:The extravasation of cytotoxic agents into subcutaneous tissue is a serious complication of chemotherapy. Unfortunately, if such extravasation occurs into the pleural space, limited data is available to guide appropriate management. We present the first report in the literature of video-assisted thoracoscopy combined ...

journal_title：Thoracic cancer

authors： Aguirre VJ,Barnett D,Burdett N,Joshi R,Viana FF

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...

journal_title：Thoracic cancer

authors： Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...

journal_title：Thoracic cancer

authors： Kim TO,Oh IJ,Kho BG,Park HY,Chang JS,Park CK,Shin HJ,Lim JH,Kwon YS,Kim YI,Lim SC,Kim YC,Choi YD

更新日期：2018-07-01 00:00:00

abstract：:This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...

journal_title：Thoracic cancer

authors： Liu YW,Chou SH,Hung JY,Kao CN,Chang PC

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:We explored correlations between the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, epidermal growth factor receptor (EGFR) mutation status, and prognosis. METHODS:Data from 293 patients with lung adenocarcinoma were classifi...

journal_title：Thoracic cancer

authors： Guo Z,Yi F,Yin W,Zhang Y,Li Q,Gu Y,Xiao Y,Cao B,Ma L,Liang L

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:This study was conducted to investigate the gene expression profiles associated with thymoma to better understand the molecular mechanism underlying the pathogenesis of thymoma. METHODS:Eight patients with thymomas (type A, AB, B1, and B2) and four controls with thymic cysts were analyzed using microarray p...

journal_title：Thoracic cancer

authors： Meng FJ,Wang S,Zhang J,Yan YJ,Wang CY,Yang CR,Guan ZY,Wang CL

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known ...

journal_title：Thoracic cancer

authors： Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

更新日期：2019-04-01 00:00:00

abstract：:We report a case of primary inflammatory myofibroblastic tumor of the diaphragm in a 64-year-old man. The patient was hospitalized for a computed tomography (CT)-detected large tissue mass at the left lower lung field. Complete tumor excision followed by pathological investigation was performed. Microscopically, the t...

journal_title：Thoracic cancer

authors： Fu J,Wu Q,Zhang Y,Zhang X,Wang Z

更新日期：2013-11-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy-related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the usage, dosage and c...

journal_title：Thoracic cancer

authors： Wang H,Zhou J,Guo X,Li Y,Duan L,Si X,Zhang L

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. METHODS:Data of patients diagno...

journal_title：Thoracic cancer

authors： Yang Q,Xu Z,Chen X,Zheng L,Yu Y,Zhao X,Chen M,Luo B,Wang J,Sun J

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND:The five-year survival rate of lung adenocarcinoma patients (LUAD) is very low,and the methods of predicting survival are a great obstacle for LUAD therapies. Endothelin receptor type B (EDNRB) gene is associated with tumorigenesis. In this study, we aimed to evaluate the predictive value of EDNRB on LUAD. ...

journal_title：Thoracic cancer

authors： Wei F,Ge Y,Li W,Wang X,Chen B

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...

journal_title：Thoracic cancer

authors： Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Y

更新日期：2020-01-01 00:00:00

abstract：:Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...

journal_title：Thoracic cancer

authors： Cheng Y,Yu Q,Xiong Y,Guo C,Nie L

更新日期：2021-01-12 00:00:00

abstract：BACKGROUND:Uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. METHODS:Eligibility cr...

journal_title：Thoracic cancer

authors： Fukuda M,Suetsugu T,Shimada M,Kitazaki T,Hashiguchi K,Kishimoto J,Harada T,Seto T,Ebi N,Takayama K,Sugio K,Semba H,Nakanishi Y,Ichinose Y

更新日期：2016-07-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...

journal_title：Thoracic cancer

authors： Zhuo M,Zheng Q,Chi Y,Jia B,Zhao J,Wu M,An T,Wang Y,Li J,Zhao X,Yang X,Zhong J,Chen H,Dong Z,Wang J,Zhai X,Wang Z

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dos...

journal_title：Thoracic cancer

authors： Fukuda M,Shimada M,Kitazaki T,Nagashima S,Hashiguchi K,Ebi N,Takayama K,Nakanishi Y,Semba H,Harada T,Seto T,Okamoto I,Ichinose Y,Sugio K

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Capn4 and ZEB1 play important roles in the metastasis of several types of cancer. However, the roles and relationship of Capn4 and ZEB1 in esophageal squamous cell carcinoma (ESCC) remain unclear. METHODS:ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patient...

journal_title：Thoracic cancer

authors： Zhao YL,Li JB,Li YJ,Li SJ,Zhou SH,Xia H

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis (LM) treatment in recent years. METHODS:This paper reports two cases of advanced lung adenocarcinoma with exon-EGFR19 mutation. LM occurred during gefit...

journal_title：Thoracic cancer

authors： Xing P,Li J,Shi Y,Zhang X

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

journal_title：Thoracic cancer

authors： Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

journal_title：Thoracic cancer

authors： Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

更新日期：2013-05-01 00:00:00

abstract：:A diagnostic work-up to evaluate possible mediastinal lymph node involvement in patients with non-small cell lung cancer (NSCLC) should be performed once suspected as a result of computed tomography. Cytological/histological verification is always compulsory. In recent years, diagnostic tools for mediastinal evaluatio...

journal_title：Thoracic cancer

authors： Dango S,Guenter J,Passlick B

更新日期：2010-07-01 00:00:00

abstract：BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

journal_title：Thoracic cancer

authors： Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:Our previous study showed that SUMO1 expression is closely related to progression in non-small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated. METHODS:SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short h...

journal_title：Thoracic cancer

authors： Ke C,Zhu K,Sun Y,Ni Y,Zhang Z,Li X

更新日期：2019-01-01 00:00:00

abstract：:In the past decade, a dramatic shift has been witnessed in cancer therapy in China. Although traditional cytotoxic chemotherapy still remains the treatment of choice for many malignancies, targeted therapies are now a component of treatment for many types of cancer, including lung cancer. As molecular target agents ar...

journal_title：Thoracic cancer

authors： Wang Y,Sun Y

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:The efficacy of amrubicin for relapsed small-cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third-line amrubicin chemotherapy in patients with extensive disease (ED)-SCLC. METHODS:We retrospectively analyzed the clinical rec...

journal_title：Thoracic cancer

authors： Sonehara K,Tateishi K,Fukushima T,Komatsu M,Yamamoto H,Koizumi T,Hanaoka M

更新日期：2019-09-01 00:00:00

abstract：:Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...

journal_title：Thoracic cancer

authors： Xu S,Liu X,Liu R,Shi T,Li X,Zhong D,Wang Y,Chen G,Chen J

更新日期：2017-11-01 00:00:00

abstract：:Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...

journal_title：Thoracic cancer

authors： Masuda K,Tokito T,Azuma K,Yanagida E,Nakamura M,Naito Y,Matsuo N,Ishii H,Yamada K,Akiba J,Hoshino T

更新日期：2018-06-01 00:00:00